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Abstract
Background: Dexamethasone has been shown to reduce mortality in patients with tuberculous meningitis but the long-
term outcome of the disease is unknown.
Methods: Vietnamese adults and adolescents with tuberculous meningitis recruited to a randomised, double-blind,
placebo-controlled trial of adjunctive dexamethasone were followed-up at five years, to determine the effect of
dexamethasone on long-term survival and neurological disability.
Results: 545 patients were randomised to receive either dexamethasone (274 patients) or placebo (271 patients). 50
patients (9.2%) were lost to follow-up at five years. In all patients two-year survival, probabilities tended to be higher in the
dexamethasone arm (0.63 versus 0.55; p=0.07) but five-year survival rates were similar (0.54 versus 0.51, p=0.51) in both
groups. In patients with grade 1 TBM, but not with grade 2 or grade 3 TBM, the benefit of dexamethasone treatment tended
to persist over time (five-year survival probabilities 0.69 versus 0.55, p=0.07) but there was no conclusive evidence of
treatment effect heterogeneity by TBM grade (p=0.36). The dexamethasone group had a similar proportion of severely
disabled patients among survivors at five years as the placebo group (17/128, 13.2% vs. 17/116, 14.7%) and there was no
significant association between dexamethasone treatment and disability status at five years (p=0.32).
Conclusions: Adjunctive dexamethasone appears to improve the probability of survival in patients with TBM, until at least
two years of follow-up. We could not demonstrate a five-year survival benefit of dexamethasone treatment which may be
confined to patients with grade 1 TBM.
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Introduction
Tuberculous meningitis (TBM) is the most severe form of M.
tuberculosis infection and kills or disables more than half of those
affected [1]. The use of adjunctive corticosteroids to attenuate the
inflammatory response in TBM may improve outcome by
reducing the likelihood or severity of neurological complications.
Over the past sixty years, a number of clinical studies have
investigated this hypothesis using adjunctive corticosteroids in the
treatment of TBM [2,3,4,5,6,7,8]. A decade ago a meta-analysis of
all randomised controlled trials suggested that adjunctive cortico-
steroids reduced the risk of death in children but not in adults [9].
We have previously conducted a randomised, double-blind,
placebo-controlled trial of adjunctive dexamethasone in 545
Vietnamese adolescents and adults with TBM [1]. Treatment
with dexamethasone was associated with a reduction in
mortality [relative risk (RR) 0.69, 95% confidence interval
(C.I.) 0.52 – 0.92, p=0.01), but not in neurological disability,
compared with placebo. Significantly fewer adverse events
occurred in the dexamethasone group than in the placebo
group. Although the number of HIV-infected patients included
in the study was too small to confidently determine a treatment
effect, the use of dexamethasone appeared to be safe in that
group of patients.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27821A more recent meta-analysis of 1140 participants recruited to
seven trials has found that corticosteroids reduced the risk of death
(RR 0.78, 95% CI 0.67–0.91)[10]. Data on disabling residual
neurological deficit from 720 participants in three trials showed that
corticosteroids reduce the risk of death or disabling residual
neurological deficit (RR 0.82, 95% CI 0.70 to 0.97). The authors
concluded that corticosteroids should be routinely used in HIV-
uninfected patients with TBM to reduce death and disabling
residual neurological deficit amongst survivors. Consequently,
adjunctive corticosteroids have become recommended as routine
therapy for all patients with TBM [10,11,12].
There are limited data on the long-term outcome of patients
with TBM [13,14]. The mechanisms by which corticosteroids
reduce mortality remain obscure [15]. It is unknown how long the
mortality benefit persists for, or whether the lack of effect on
disability will have long-term consequences. Therefore we
conducted a follow-up study to determine whether adjunctive
dexamethasone was associated with reduced mortality or neuro-
logical disability five years after entry into the original trial.
Methods
Study design, setting and participants
The original study was a randomised, double-blind, placebo-
controlled trial of adjunctive dexamethasone in Vietnamese adults
and adolescents with TBM. Participants were recruited from two
centres in Ho Chi Minh City, Vietnam: Pham Ngoc Thach
Hospital and the Hospital for Tropical Diseases. Subjects were
eligible to enter the trial if they were aged 15 years or older and
had clinically suspected TBM. Details of the study design and
analysis have been previously reported [1]. The primary outcome
of the original study was death and disability at nine months after
randomization. The protocol for this trial and the supporting
CONSORT checklist are available as supporting information; see
Protocol S1 and Checklist S1.
Treatments
Adults previously untreated for tuberculosis received three
months of daily oral isoniazid (5 mg/kg), rifampin (10 mg/kg),
pyrazinamide (25 mg/kg; maximum dose 2g/day), and intramus-
cular streptomycin (20 mg/kg, maximum dose1g/day), followed
by six months of isoniazid and rifampin at the same daily doses,
according to Vietnamese national guidelines. Ethambutol (20 mg/
kg, maximum dose 1.2 g /day) was substituted for streptomycin in
HIV-infected patients, and was added to the regimen for the first
three months in patients who had previously received treatment
for tuberculosis. Antiretroviral therapy was not available at the
time of the study.
Patients were randomized to receive treatment with either
intravenous dexamethasone (0.3 to 0.4 mg/kg day) according to
Figure 1. Kaplan-Meier curves (left panel) and hazard rate estimates (right panel) according to treatment group. The blue solid lines
correspond to the placebo group, the dashed red lines to the dexamethasone group.
doi:10.1371/journal.pone.0027821.g001
Figure 2. Kaplan-Meier curves by TBM grade. The blue solid lines correspond to the placebo group, the dashed red lines to the dexamethasone
group.
doi:10.1371/journal.pone.0027821.g002
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identical placebo as previously described [1].
Outcome at nine months
Treatment with dexamethasone was associated with a reduced
risk of death in all patients (RR 0.69, 95% C.I. 0.52 to 0.92,
p=0.01). The relative risk for dying during the nine month follow
up of the original study was 0.47 (95% C.I. 0.25 – 0.9 p=0.02) in
grade 1 TBM patients, 0.71 (95% C.I. 0.46 – 1.1 p=0.11) in grade
2 TBM patients, and 0.81 (95% C.I. 0.51 – 1.29 p=0.38) in grade
3 TBM patients. Dexamethasone was not associated with a
significant reduction in the proportion of severely disabled patients
[34 /187 patients (18.2%) among survivors in the dexamethasone
group versus 22/159 patients (13.8%) in the placebo group,
p=0.27], or in the proportion of patients who had either died or
were severely disabled after nine months (odds ratio 0.81, 95%
C.I. 0.58 to 1.13, p=0.22).
Follow-up study
Participants were contacted by letter and/or telephone and
invited to attend for a clinical assessment five years after
randomization into the original study. If the patient had died
prior to the follow-up assessment, the date and cause of death was
requested from the relatives. Patients were assessed using a
standard questionnaire and neurological examination. Neurolog-
ical disability was assessed using standardized questionnaires (’two
simple questions’ and modified Rankin scale), as previously
described [1]. Four survivors who were unable to attend the
hospital gave verbal consent and were assessed by telephone
interview. The primary outcome was overall survival during the
five years of follow-up. The secondary outcome measures were
disability status five years after randomization, and tuberculosis
relapse (defined as re-treatment for tuberculosis) during the follow-
up period. All data were recorded prospectively into individual
case record forms entered into an electronic database (Microsoft
Access 2003) and double-checked by the principal investigator
prior to analysis.
Ethics statement
Written informed consent was obtained for participation in the
study. The study was conducted according to the ethical principles
expressed in the Declaration of Helsinki. The study was approved
by the institutional review boards of the participating hospitals
(Scientific and Ethical Committee of the Hospital for Tropical
Diseases, Scientific and Ethical Committee of Pham Ngoc Thach
Hospital), and the Oxford Tropical Research Ethics Committee.
The study was registered with ClinicalTrials.gov registry, identifier
number NCT01317654.
Statistical analysis
Survival curves were visualized using Kaplan-Meier estimators.
We also displayed hazard rate estimates (number of events divided
Table 1. Kaplan-Meier survival estimates at one to five years of follow-up for all patients and in the subgroups defined by TBM
grade.
Dexamethasone group
survival rate (95% CI)
Placebo group
survival rate (95% CI) Difference (95% CI), p-value
p-value for
heterogeneity*
At 1 year
All patients (n=545)
0.65 (0.60 to 0.71) 0.57 (0.51 to 0.63) 0.09 (0.00 to 0.17); p=0.04 0.29
TBM grade 1 (n=176) 0.82 (0.74 to 0.90) 0.66 (0.57 to 0.77) 0.15 (0.02 to 0.29); p=0.02
TBM grade 2 (n=247) 0.66 (0.58 to 0.75) 0.59 (0.51 to 0.68) 0.07 (-0.05 to 0.19); p=0.25
TBM grade 3 (n=122) 0.41 (0.30 to 0.55) 0.39 (0.29 to 0.54) 0.01 (-0.16 to 0.19); p=0.88
At 2 years
All patients (n=545)
0.63 (0.57 to 0.69) 0.55 (0.49 to 0.61) 0.08 ( 0.00 to 0.16); p=0.07 0.25
TBM grade 1 (n=176) 0.79 (0.71 to 0.88) 0.63 (0.54 to 0.75) 0.16 ( 0.02 to 0.29); p=0.02
TBM grade 2 (n=247) 0.63 (0.55 to 0.72) 0.57 (0.49 to 0.66) 0.06 (-0.06 to 0.19); p=0.33
TBM grade 3 (n=122) 0.39 (0.28 to 0.54) 0.39 (0.29 to 0.54) 0.00 (-0.18 to 0.17); p=0.96
At 3 years
All patients (n=545)
0.61 (0.55 to 0.67) 0.55 (0.49 to 0.61) 0.06 (-0.02 to 0.15); p=0.15 0.26
TBM grade 1 (n=176) 0.77 (0.68 to 0.86) 0.62 (0.52 to 0.74) 0.15 (0.01 to 0.29); p=0.04
TBM grade 2 (n=247) 0.60 (0.52 to 0.70) 0.57 (0.49 to 0.66) 0.03 (-0.09 to 0.16); p=0.59
TBM grade 3 (n=122) 0.39 (0.28 to 0.54) 0.39 (0.29 to 0.54) 0.00 (-0.18 to 0.17); p=0.96
At 4 years
All patients (n=545)
0.55 (0.50 to 0.62) 0.53 (0.47 to 0.59) 0.03 (-0.06 to 0.11); p=0.56 0.35
TBM grade 1 (n=176) 0.69 (0.59 to 0.80) 0.60 (0.50 to 0.72) 0.08 (-0.06 to 0.23); p=0.27
TBM grade 2 (n=247) 0.55 (0.46 to 0.65) 0.55 (0.47 to 0.65) 0.00 (-0.13 to 0.12); p=0.96
TBM grade 3 (n=122) 0.37 (0.27 to 0.52) 0.38 (0.27 to 0.52) 0.00 (-0.18 to 0.17); p=0.98
At 5 years
All patients (n=545)
0.54 (0.48 to 0.60) 0.51 (0.45 to 0.57) 0.03 (-0.06 to 0.12); p=0.51 0.36
TBM grade 1 (n=176) 0.69 (0.59 to 0.80) 0.55 (0.44 to 0.68) 0.14 (-0.01 to 0.29); p=0.07
TBM grade 2 (n=247) 0.52 (0.43 to 0.62) 0.54 (0.46 to 0.64) -0.02 (-0.15 to 0.11); p=0.73
TBM grade 3 (n=122) 0.35 (0.25 to 0.50) 0.38 (0.27 to 0.52) -0.02 (-0.20 to 0.15); p=0.81
*Interaction test of dexamethasone treatment with TBM grade based on a logistic regression for the outcome death and excluding censored patients
doi:10.1371/journal.pone.0027821.t001
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time intervals: 0 to three, three to six, six to nine, nine to twelve
months, and at yearly intervals thereafter. As supplementary
graphical displays, we show the Nelson-Aaalen estimator of the
cumulative hazard and smoothed hazard rate estimates based on a
local bandwidth selection algorithm.
Proportional hazards were tested based on weighted Schoenfeld
residuals. As there was strong evidence of non-proportional
hazards for the treatment effect over time, we compared survival
probabilities at fixed time points (yearly intervals from one to five
years of follow-up) in all patients and by TBM grade, respectively.
Kaplan-Meier estimates of survival probabilities were used and
comparisons were based on Greenwood’s variance formula. We
also tested whether there was an interaction between TBM grade
and dexamethasone treatment using a logistic regression, with
outcome death prior to the respective time point, and excluding
patients lost to follow-up. In addition, we fitted separate Cox
survival models for the first three months of randomized treatment
and the time thereafter. The following potential predictors of
mortality were included in the Cox regression analysis: treatment
group, admission TBM grade, HIV status, age, gender, haema-
tocrit and serum sodium at baseline. The three-month cut-off was
chosen because at this time point the initiation phase of
tuberculosis treatment (and treatment with dexamethasone) had
been completed. Of note, estimates (of hazards and hazard ratios)
for the time period from month three onwards include only
patients who survived beyond month three and this may select
different subpopulations in the two treatment arms. Thus, causal
interpretation of results from the latter time period should be
applied with caution. All reported confidence intervals are two-
sided 95% confidence intervals and analyses were performed with
the statistical software R version 2.8.0 (R Foundation for Statistical
Computing, Vienna, Austria) [16] and the companion R package
muhaz version 1.2.5 (for smooth hazard estimation).
Results
545 patients were randomized (274 in the dexamethasone arm,
271 in the placebo arm) between 4 April 2001 and 29 March
2003. 10/545 (2%) patients were lost to follow-up during the
original nine-month follow-up period (5 in the dexamethasone
group and 5 in the placebo group). A further 40 patients (18 in the
dexamethasone group and 22 in the placebo group) were lost
between nine months and five years, giving a total loss-to-follow-
up of 9.2%. The median (IQR) timing of the follow-up visit for the
survivors was 5.2 (4.7–5.5) years after randomization.
The baseline characteristics of the study participants are
reported in the original publication [1]. In brief, the median age
was 35 years (range 15 to 88 years), 61% were male, 18% were
HIV-infected, and the distribution of patients with TBM grade 1,
2 and 3 was 32%, 45%, and 23%, respectively.
A total of 249 subjects (121 in the dexamethasone arm and 128
in the placebo arm) died during the five-year follow-up period. 148
patients (59 dexamethasone group versus 89 placebo group) died
in the first three months after randomization; 51 subjects (28
dexamethasone group versus 23 placebo group) died during
months three to nine, and 50 patients (34 dexamethasone group
versus 16 placebo group) died after month nine. Of the 50 subjects
who died after nine months, 4 had a cause of death reported by the
relatives (TBM, pneumonia and diabetes, myocardial infarction
and asthma) and 46 had an unknown cause of death. There is no
national mortality register in Vietnam and we were therefore
unable to independently verify cause of death. Kaplan-Meier
estimates of mortality in all patients are displayed in Figure 1 (left
panel) and by TBM grade in Figure 2. Two-year survival
probabilities tended to be higher in the dexamethasone arm
(0.63 vs. 0.55; p=0.07) but five-year estimates were similar (0.54
Table 3. Disability status at 9 months and 5 years post-
randomisation.
Dexamethasone group Placebo group
Outcome at 9 months N=274 N=271
Good 104 (38%) 95 (35.1%)
Intermediate 49 (17.9%) 42 (15.5%)
Severe 34 (12.4%) 22 (8.1%)
Dead 87 (31.8%) 112 (41.3%)
Outcome at 5 years N=250 N=243
Good 69 (27.6%) 61 (25.1%)
Intermediate 43 (17.2%) 36 (14.8%)
Severe 17 (6.8%) 18 (7.4%)
Dead 121 (48.4%) 128 (52.7%)
doi:10.1371/journal.pone.0027821.t003
Table 2. Cox regression analysis of mortality in months 0 to 3, and from month 3 onwards.
Covariate Months 0 to 3 After month 3
HR 95% CI p-value HR 95% CI p-value
Treatment with dexamethasone 0.62 0.44-0.88 0.01 1.50 1.00-2.26 0.05
Grade 2 TBM versus grade 1 TBM
£ 1.81 1.12-2.91 0.02 1.18 0.76-1.84 0.45
Grade 3 TBM versus grade TBM
£ 3.81 2.32-6.24 ,0.001 1.44 0.81-2.57 0.22
HIV positive versus HIV negative
$ 2.15 1.39-3.32 ,0.001 9.93 6.03-16.35 ,0.001
HIV status unknown* vs HIV negative
$ 16.20 7.67-34.23 ,0.001 - - -
Age (by +10 years) 1.06 0.95-1.17 0.29 1.28 1.13-1.45 ,0.001
Haematocrit (by +10%) 0.95 0.73-1.23 0.68 0.68 0.49-0.94 0.02
*All patients with unknown HIV status died within the first 3 months.
£ Tests for interaction of TBM grade with treatment: p=0.46 (months 0-3) and p=0.18 (after month 3).
$ Tests for interaction of HIV status with treatment: p=0.29 (months 0-3) and p=0.17 (after month 3).
Gender and serum sodium were not significant in either model and didn’t affect the other parameters. They were therefore omitted from the final mode.
doi:10.1371/journal.pone.0027821.t002
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not in grade 2 or grade 3 TBM the benefit of dexamethasone
treatment tended to persist over time (five-year survival probabil-
ities 0.69 vs. 0.55, p=0.07) but there was no conclusive evidence
of treatment effect heterogeneity by TBM grade (p=0.36)
(Table 1).
Survival curves corresponding to the two treatment arms got
closer or crossed over with increasing time, a typical indication of
non-proportional hazards. Indeed there was strong evidence of
non-proportional hazards of the treatment effect over time both in
an unadjusted analysis (p=0.004) and in an analysis adjusted for
TBM grade and HIV status (p=0.007). Figure 1 (right panel)
displays hazard rate estimates in different time intervals and
displays a strong reduction in hazard due to dexamethasone
during the first three months, but similar hazards in both arms
from month three onwards. We also performed Nelson-Aalen
estimate of cumulative hazards and hazard estimates based on
kernel-based methods according to treatment arm (Figure S1).
Adjusted Cox regression analyses for both time periods are
displayed in Table 2. For the first three months, the hazard of
death was highly significantly reduced for subjects in the
dexamethasone arm [hazard ratio (HR)=0.62, 95% CI 0.44–
0.88, p=0.01]; TBM grade 2 or 3 and HIV infection were
independent risk factors for death. In contrast, the hazard for
subjects in the dexamethasone arm (and still alive by month 3) was
increased after three months (HR=1.50, 95% CI 1.00–2.26,
p=0.05); HIV infection, increasing age, and lower haematocrit,
but not TBM grade, were independent risk factors for death.
Antiretroviral therapy was not available during the time of the
initial study (2001–2004) and there was limited availability
thereafter. To our knowledge none of the HIV-infected patients
received antiretroviral therapy.
As described in the methods section, our choice of the cut-point
at 3 months for our Cox regression analysis was based on clinical
grounds and the resulting Cox regression models for the two
periods showed no evidence of non-proportional hazards for the
study drug effect (p=0.66 for the first period, p=0.18 for the
second period). However, exploratory data-driven analyses suggest
a somewhat higher cut-point of around 7 months with values up to
9 months for the true change point being compatible with the
data. Importantly however, the selection of the cut-point had little
impact on covariate effects. For example, a cut-point selection of 9
months lead to the same significant covariates for both periods
except that baseline hematocrit was no longer significant for the
period after 9 months (p=0.28) but became borderline significant
for the early period (p=0.08).
Disability status at the five-year follow-up was available for 493
(90.5%) of patients and is displayed in table 3. There was no
significant association between randomized treatment and
disability status at five years (p-value linear trend test=0.32).
There was, however, a highly significant association between
disability status at nine months and five years (p,0.001). Indeed
the proportions of patients with severe disability or death at five
years were 1.2% and 11.3%, respectively, in 168 patients with
good outcome at nine months, compared with 12.5% and 20% in
80 patients with intermediate outcome at nine months, and
50.0% and 32.6% in 46 patients with severe disability at nine
months.
Of 246 individuals who were alive at the time of the five-year
interview, only three (all in the placebo group) reported that they
had received re-treatment for TB. It was not possible to assess
whether patients who had died between nine months and five
years had been re-treated for tuberculosis prior to death.
Discussion
Our original trial [1] showed that adjunctive dexamethasone
treatment improved survival in patients with TBM at nine months.
The present study shows a survival benefit of dexamethasone
treatment for up to two years of follow-up. The benefits on long-
term (five-year) survival are inevitably less clear, and may be
confined to patients with grade I TBM, and dexamethasone was
not associated with improvement in disability status at nine
months or five years post-randomisation.
We managed to obtain follow-up data from the vast majority
(91.2%) of patients at five years. Although the five-year survival
estimates were similar in the two arms, there did appear to be a
persistent benefit of dexamethasone in the patients with grade 1
TBM. One possible explanation is that dexamethasone may
prevent the development of neurological complications in this
group of patients, whereas it has limited effect on those who
present with established neurological deficits (grade 2 or 3 TBM).
This has important clinical implications and re-emphasises the
need to diagnose and treat TBM promptly, before neurological
complications ensue. Although TBM may have an indolent
presentation, once a patient comes to the attention of medical
services, the condition should be managed as a medical
emergency, as clinical outcome is critically dependent on the
TBM grade at the initiation of therapy.
We observed that the Kaplan-Meier survival curve for all
patients converged over the five-year follow-up period, suggesting
non-proportional hazards. This was confirmed by a Cox survival
hazards model which indicated that dexamethasone had a highly
significant benefit during the first three months of follow-up which
was partially offset by a higher subsequent mortality amongst
three-month survivors in the dexamethasone group. A possible
explanation is that dexamethasone saves lives acutely, but leaves
some individuals with severe neurological sequaelae, which
subsequently lead to death. Two baseline variables, HIV status
and increased TBM grade, were found to be associated with death
during the initial 3 months of treatment. When we examined the
follow-up period beyond three months, HIV status, low haema-
tocrit and increased age were found to be independently associated
with death.
Disability status at nine months and five years was assessed
using the modified Rankin score and the ’two simple questions’.
These tools are commonly used for assessment of disability in
stroke patients and give an indication of the extent to which
patients require physical assistance with activities of daily living, a
somewhat crude measure of disability. Examination of the
disability data at nine months reveals that severe disability was
more frequent in the dexamethasone arm compared with the
placebo arm (12.4% versus 8.1%), and that intermediate outcome
showed a similar pattern (17.9% versus 15.5%, respectively).
There was no difference in the number of patients with TBM
grade 1 who had severe disability at nine months (four in each
treatment arm); this low rate of disability at nine months may
explain why the survival benefit in grade 1 TBM appears to persist
out to five years. For patients with grade 2 and 3 TBM there were
more severely disabled patients at 9 months in the dexamethasone
arm, compared with the placebo arm: 19 versus 11 (grade 2 TBM)
and 11 versus 7 (grade 3 TBM). By five years intermediate
outcome remained more frequent in the dexamethasone arm
compared with the placebo (17.2% versus 14.8%) but the rates of
severe outcome were similar (6.8% versus 7.4%). Thus dexameth-
asone may be preventing death at nine months but leaving more
patients disabled; these disabled patients go on to die over the
course of the follow-up period.
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outcome measure was all-cause mortality at five years and it was
not possible to determine whether the cause of death was related to
TBM or not. Secondly, we did not formally assess neuro-cognitive
function in the patients, which may have been able to detect more
subtle differences in disability. Thirdly, our Kaplan-Meier curves
and analyses suggest a larger benefit of dexamethasone treatment
in TBM grade 1 but tests for heterogeneity of the treatment effect
in different TBM grades were not significant. While such tests
have low power, we cannot conclusively rule out that the observed
heterogeneity is due to chance alone. The sample size in the
original study was powered to detect a difference in the primary
endpoint outcome at nine months; no sample size was calculated
in relation to the five-year follow up outlined in this study. Finally,
there are no specialist neuro-rehabilitation services available in
Vietnam and this may influence long-term outcome of disabled
patients; these results may therefore not be comparable to
outcome for disabled TBM survivors in settings where such
facilities exist.
The findings of our original study indicated that dexamethasone
improved survival at nine months in all patients with TBM,
although it had no effect on neurological disability. This study
demonstrated a benefit of dexamethasone up to two years of
follow-up but could not demonstrate a five year survival benefit,
which may be confined to patients with less severe disease.
Supporting Information
Figure S1 Cumulative hazard (left panel) and smoothed hazard
rate estimates (right panel) according to treatment group. The blue
solid lines correspond to the placebo group, the dashed red lines to
the dexamethasone group. The blue dash-dotted and the red
dotted lines display the cumulative hazards for the two groups in
TBM grade 1 patients only.
(TIF)
Protocol S1 Trial Protocol.
(DOC)
Checklist S1 CONSORT Checklist
(DOC)
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